Genedata Completes Important Milestone in Collaboration with Bayer Pharma AG
News Sep 24, 2015
Genedata has announced the successful delivery of an important milestone in its collaboration with Bayer Pharma AG to create an advanced security-hardened research data platform to manage, process and analyze exploratory NGS and other omics data from patients and pre-clinical experiments.
The platform is based on Genedata Profiler, an open, interoperable enterprise software system designed to facilitate efficient patient and compound profiling processes. Genedata Profiler was launched by Genedata in April this year and is available immediately to interested parties.
Pharmaceutical companies are continuously accelerating the development of drugs that efficiently treat a targeted, molecular sub-population of patients. Integral to this aim is the ability to delve deeper into omics data from patients and patient-derived models in order to increase knowledge about specific disease states and drug treatment responses.
Harnessing the data storage and virtualization capabilities of iRODS, an open source middleware software system, to the data management, processing and analysis power of Genedata Profiler, Bayer Pharma AG and Genedata have created a research data platform to maximize the utility and usability of the vast amounts of patient-related multi-omics data available.
The integration of Genedata Profiler with iRODS ensures chain of custody of the entire omics data analysis workflow, thereby significantly enhancing the security of the data and ensuring the privacy of patients being studied. The platform enables researchers to work with data from clinical and preclinical environments, linking traditionally disconnected R&D data silos.
Genedata Profiler enables integration of disease and genomic information from different studies and facilitates research teams in geographically distributed environments to securely manage, share and analyze on a global scale the clinical multi-omics data amassed during their translational research efforts. It translates NGS data into knowledge for target and biomarker discovery and patient selection, and to generate reproducible, reliable conclusions about disease causes, risks, and drug responses.
At the same time, increasingly complex compliance and data management challenges in the areas of patient privacy and security are met by the cutting-edge security features of Genedata Profiler, establishing a chain of custody for analyzing personalized medicine data.
“We are pleased that our successful collaboration with Bayer Pharma AG has resulted in the establishment of a state-of-the-art translational research data platform that allows interdisciplinary and geographically dispersed teams of researchers to work with patient-related NGS data. This solution ensures that only properly authenticated and authorized researchers have access to this sensitive information,” said Dr. Othmar Pfannes, CEO of Genedata. “Genedata Profiler moves applied precision medicine into a new era, where petabytes of genomic data can be securely accessed, shared, analyzed and interpreted on a global scale. We are committed to the continued development of Genedata Profiler to make it the platform of choice for all omics-based profiling processes for patients and compounds.”
Genedata is the trusted partner of all 25 of the top 25 pharma companies for R&D software solutions. Genedata Profiler will be demonstrated at the 13th Annual Pharmaceutical IT Congress 2015 in London, September 23-24, 2015.
Large-scale supercomputing is essential to solving complex questions about our world. But storage platforms essential for these advanced computer systems have been stuck in a rigid framework that required users to either choose between customization of features or high availability. Now, researchers have found a way to give high-performance computing data systems the flexibility to thrive with a framework called BespoKV, perhaps helping to one day achieve the HPC goal of performing at the exascale, or 1 billion billion calculations per second.READ MORE